Tenaya Therapeutics(TNYA) - 2023 Q4 - Annual Results

Exhibit 99.1 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from Recent Financing Extends Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., March 18, 2024 -- Tenaya Therapeuti ...